|
Zeitpunkt |
Session |
Titel / Beschreibung |
Autoren / Interviewdetails |
|
|
Mittwoch, 19.12.01 |
|
Was gab es neues auf der ICAAC und Bill Craigs neueste PK/PD - Daten. |
Prof. Dr. William Craig, Madison, WI, USA |
|
|
Mittwoch, 19.12.01 |
|
Was gab es neues auf der ICAAC. |
Prof. Dr. George Drusano, Albany, NY |
|
|
Mittwoch, 19.12.01,
10:00 Uhr |
|
MRSA - die Situation in den USA und PK/PD von Piperacillin / Tazobactam. |
Dr. David Nicolau, Hartford, CT, USA |
|
|
Mittwoch, 19.12.01,
09:30 Uhr |
|
MHK - Bestimmung und Optimierung der Therapie nach PK/PD - Prinzipien. |
Dr. Johan Mouton, Nijmegen, Holland |
|
|
Mittwoch, 19.12.01,
10:00 - 11:30 Uhr |
230. In Vitro Susceptibility: Miscellaneous |
2264. Surveillance of Susceptibility Patterns in 1297 European and US Anaerobic and Micro-Aerophilic Isolates to Amoxicillin/Clavulanic Acid (A/C) and 5 Other Agents |
L. M. KOETH1, M. R. BISCOTTI1, P. C. APPELBAUM2, L. J. DUBREUIL3, E. J. C. GOLDSTEIN4, A. C. RODLOFF5;
1Laboratory Specialists Inc, Cleveland, OH, 2Hershey Medical Center, Hershey, PA, 3University of Lille, Lille, France, 4RM Alden Research Foundation, Los Angeles, CA, 5University of Leipzig, Leipzig, Germany. |
P.1
P.2
|
|
Mittwoch, 19.12.01,
10:00 - 11:30 Uhr |
230. In Vitro Susceptibility: Miscellaneous |
2264. Surveillance of Susceptibility Patterns in 1297 European and US Anaerobic and Micro-Aerophilic Isolates to Amoxicillin/Clavulanic Acid (A/C) and 5 Other Agents |
L. M. KOETH1, M. R. BISCOTTI1, P. C. APPELBAUM2, L. J. DUBREUIL3, E. J. C. GOLDSTEIN4, A. C. RODLOFF5;
1Laboratory Specialists Inc, Cleveland, OH, 2Hershey Medical Center, Hershey, PA, 3University of Lille, Lille, France, 4RM Alden Research Foundation, Los Angeles, CA, 5University of Leipzig, Leipzig, Germany. |
|
|
Mittwoch, 19.12.01,
10:00 - 11:30 Uhr |
224. Antimicrobial Pharmaco |
2197. Influence of Linezolid (L), Penicillin (P), and Clindamycin (C), Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A (SPE A) Release |
E.A. COYLE1, R. CHA2, M.J. RYBAK2,3;
1The Univ. of Houston Coll. of Pharmacy, Houston, TX, 2The Anti-Infective Res. Lab., Coll. Of Pharmacy and Allied Health Professions, Wayne State Univ., Detroit, MI, 3Sch. of Med., Detroit, MI. |
P.1
P.2
|
|
Mittwoch, 19.12.01,
10:00 - 11:30 Uhr |
224. Antimicrobial Pharmaco |
2190. Pharmacodynamic (PD) Evaluation of Extending the Infusion Time of Piperacillin/tazobactam (P/T) Doses Using Monte Carlo Analysis (MC) |
B. M. LOMAESTRO1, K. A. RODVOLD2, L. H. DANZIGER2, G. L. DRUSANO3;
1Albany Medical Center Hospital, Albany, NY, 2University of Illinois College of Pharmacy, Chicago, IL, 3Albany Medical College, Albany, NY. |
P.1
P.2
P.3
P.4
P.5
|
|
Mittwoch, 19.12.01,
8:30 - 10:00 Uhr |
217. Pharmacodynamics of Antimicrobials II: In Vivo Models |
2096. Pharmacodynamic (PD) Parameters of Linezolid Associated with Efficacy vs. Streptococcus pneumoniae-Induced Acute Otitis Media (AOM) in Gerbils |
W. HUMPHREY, M. SHATTUCK, K. KOLBASA, R. ZIELINSKI, M. KUO, R. SCHAADT, G. ZURENKO, I. RICHARDS;
Pharmacia Corp., Kalamazoo, MI. |
P.1
P.2
|
|
Mittwoch, 19.12.01,
8:30 - 10:00 Uhr |
217. Pharmacodynamics of Antimicrobials II: In Vivo Models |
2089. In Vivo Pharmacodynamic Activity of Ceftriaxone against Viridans Streptococci: Implications for Susceptibility Breakpoints |
W. A. CRAIG, D. ANDES;
Univ. of Wisconsin and VA Hosp., Madison, WI. |
|
|
Mittwoch, 19.12.01,
8:30 - 10:00 Uhr |
216. Pharmacodynamics of Antimicrobials I: In Vitro Models |
2088. Pharmacodynamic Studies of Different Dosage Regimens of Amoxicillin/ Clavulanic Acid Including a New Slow-Release Formulation against in an In Vitro Kinetic Model |
INGA ODENHOLT1, E. LÖWDIN2, O. CARS3;
1Dep. of Infectious Diseases, University Hospital, Malmö, Sweden, 2University Hospital, Uppsala, Sweden, 3University hospital, Uppsala, Sweden. |
|
|
Mittwoch, 19.12.01,
8:30 - 10:00 Uhr |
216. Pharmacodynamics of Antimicrobials I: In Vitro Models |
2077. Pharmacodynamics of Penicillin in Combination Therapy Using Penicillinase in an In Vitro Kinetic Model |
ELISABETH M. LÖWDIN, I. ODENHOLT, S. BENGTSSON, O. CARS;
University Hospital, Uppsala, Sweden. |
P.1
P.2
|
|
Mittwoch, 19.12.01,
8:30 - 10:00 Uhr |
216. Pharmacodynamics of Antimicrobials I: In Vitro Models |
2076. Pharmacodynamics of Moxifloxacin vs Eythromycin against Intracellular in an In Vitro Kinetic Model |
E. TANO, E. LÖWDIN, O. CARS;
University Hospital, Uppsala, Sweden. |
|
|
Dienstag 18.12.01,
13:00 Uhr |
|
ICAAC 2001 Highlights: Surveillance - Studien und "Cycling" von Antibiotika. |
Interview mit Prof. Rodloff, Leipzig |
|
|
Dienstag, 18.12.01,
3:00 - 4:30 Uhr |
189. Meningitis |
1860. Evaluation of Ertapenem (ETP) against Penicillin-Sensitive and -Resistant Pneumococci in the Experimental Meningitis Model |
PH. COTTAGNOUD1, F. ACOSTA2, M. COTTAGNOUD2, M. G. TÄUBER3;
1Dept. Internal Medicine, Inselspital, Bern, Switzerland, 2Dept. Internal Medicine, Zieglerspital, Bern, Switzerland, 3Inst. for Infectious Diseases, University of Bern, Bern, Switzerland. |
|
|
Dienstag 18.12.01, 2:00 - 4:30 Uhr |
185. Pediatric Infectious Diseases |
1826. Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/Clavulanate and Cefuroxime Axetil |
D. ADAM1, H. SCHOLZ2, H. HAVERKAMP3, M. HELMERKING3;
1Dept. of Antimicrobial Therapy, Dr. v. Haunersches Children's Hosp., Univ. of Munich, Munich, Germany, 2Inst. for Infectiology, Microbiol. and Hygienics, Municipal Hosp. Buch, Berlin, Germany, 3Algora Clin. Res. Organization, Munich, Germany. |
|
|
Dienstag, 18.12.01,
13:30 - 15:00 Uhr |
171. Animal Models |
1660. Efficacy of Gatifloxacin and Moxifloxacin Compared to Ciprofloxacin against Experimental Yersinia pestis Infection in Balb/c Mice |
J. A. STEWARD, P. R. RUSSELL, T. J. G. BROOKS;
DERA, Salisbury, United Kingdom. |
|
|
Dienstag, 18.12.01 |
|
Klinische Überlegenheit von Linezolid gegenüber Glykopeptiden? Siehe auch Beitrag 1481. |
Interview mit M. Wilcox, Universitätsklinik Leeds, UK |
|
|
Dienstag, 18.12.01, 11:00 - 12:30 Uhr |
164. Clinical Candidiasis and Aspergillosis |
1624. A Double-Blind Study of Fluconazole Oral Suspension vs.Capsules in the Treatment of Oropharyngeal Candidiasis in HIV-Patients |
M. EICHEL1, C. SCHNEIDER2, G. JUST-NUEBLING2;
1University Hospital, Frankfurt/Main, Germany, 2university hospital, Frankfurt/Main, Germany. |
|
|
Dienstag, 18.12.01, 11:00 - 12:30 Uhr |
163. Animal Models of Mycoses |
1604. Evaluation of Voriconazole Efficacy in the Treatment of Murine Fusariosis |
G. H. REYES1, L. LONG2, M. HOSSAIN2, M. A. GHANNOUM1;
1Case Western Res. U./University Hosp., Cleveland, OH, 2Case Western Reserve University, Cleveland, OH. |
P.1
P.2
P.3
|
|
Dienstag, 18.12.01, 11:00 - 12:30 Uhr |
163. Animal Models of Mycoses |
1603. Development of a Quantitative PCR Assay to Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of the Efficacy of Caspofungin |
J. C. BOWMAN, G. K. ABRUZZO, J. W. ANDERSON, A. M. FLATTERY, C. J. GILL, V. B. PIKOUNIS, D. M. SCHMATZ, P. A. LIBERATOR, C. M. DOUGLAS;
Merck and Co., Inc., Rahway, NJ. |
|
|
Dienstag, 18.12.01, 9:30 - 11:00 Uhr |
156. Staphylococcal and Streptococcal Infections |
1481. Linezolid versus Teicoplanin for the Treatment of Hospitalized Patients with Gram-Positive Infections |
M. WILCOX1, T. TANG2, B. HAFKIN2;
1Leeds General Infirmary, Univ of Leeds, Leeds, United Kingdom, 2Pharmacia Corp, Peapack, NJ. |
|
|
Dienstag, 18.12.01, 9:30 - 11:00 Uhr |
155. Ventilator-Associated Pneumonia |
1469. Linezolid Efficacy in the Treatment of Ventilator-Associated Nosocomial Pneumonia |
S. K. CAMMARATA, T. H. OLIPHANT, K. A. HEMPSALL;
Pharmacia, Kalamazoo, MI. |
|
|
Dienstag, 18.12.01, 9:30 - 11:00 Uhr |
151. Nosocomial Infections IV: Legionella and Other Outbreaks |
1444. Nosocomial Sepsis Caused by Pandoraea pnomenusa Highly Resistant to Meropenem but Sensitive to Imipenem in Two Oncology Patients |
JAN P. ARENDS, LIEKE V.M. MÖLLER, RIENK Y.J. TAMMINGA;
Academic Hospital Goningen, Groningen, Netherlands. |
|
|
Dienstag, 18.12.01, 9:30 - 11:00 Uhr |
149. Linezolid In Vitro |
1421. Uptake and Intracellular Activity of Linezolid in Human Phagocytic and Tissue Cultured Epithelial Cells |
A. PASCUAL, S. BALLESTA, I. GARCÍA, E. J. PEREA;
University of Seville, Seville, Spain. |
|
|
Dienstag, 18.12.01, 9:30 - 11:00 Uhr |
149. Linezolid In Vitro |
1414. Evaluation of Linezolid Potency on Gram-Positive Cocci in an Austrian Multi-Center Study |
H. MITTERMAYER, C. JEBELEAN, ON BEHALF OF THE ALPS GROUP;
Elisabethinen Hospital, Linz, Austria. |
|
|
Montag 17.12.01,
3:00 - 4:30 Uhr |
125. Nosocomial Infections in Immunosuppressed Hosts |
1251. Oral Flora and Mucositis Grade During Myeloablative Chemotherapy |
H. LOEVENICH1, C. KEULERTZ1, H. SCHUETT-GEROWITT2, U. BETHE1, D. SOEHNGEN1, D. WALDSCHMIDT1, O. A. CORNELY1;
1University of Cologne, Dept. of Internal Med., Cologne, Germany, 2University of Cologne, Inst. of Microbiol., Cologne, Germany. |
|
|
Montag 17.12.01,
15:00 - 16:30 Uhr |
122. Nosocomial Infections I: Staphylococcus aureus |
1227. Use of Mupirocin to Prevent Methicillin Resistant Staphylococcus aureus (MRSA) Orthopedic Surgical Site Infections (SSIs) |
J. HALL, M. H. WILCOX, H. PIKE, P. TEMPLETON, W. N. FAWLEY, P. PARNELL, P. VERITY;
Dept of Microbiology & Infection Control, The General Infirmary & University of Leeds, Leeds, United Kingdom. |
|
|
Montag 17.12.01,
15:00 - 16:30 Uhr |
122. Nosocomial Infections I: Staphylococcus aureus |
1224. Risk Factors Associated with Methicillin-Resistant Staphylococcus aureus (MRSA) |
R. A. VENEZIA, E. M. GRAFFUNDER, A. M. EVANS;
Albany Medical Center, Albany, NY. |
|
|
Montag 17.12.01,
15:00 - 16:30 Uhr |
119. Antibiotic Resistance in Healthcare Settings |
1194. Risk Factors Associated with the Development of Enterococcal Resistance to Linezolid |
M. P. PAI, R. D. GONZALES, J. M. PETROLATI, M. B. GRAHAM, P. C. SCHRECKENBERGER, K. A. RODVOLD, J. P. QUINN;
University of Illinois at Chicago, Chicago, IL. |
|
|
Montag 17.12.01,
3:00 - 4:30 Uhr |
119. Antibiotic Resistance in Healthcare Settings |
1193. Emergence of Linezolid-Resistant Enterococcus faecium in the Gastrointestinal (GI) Tract during Treatment of Vancomycin-Resistant Enterococcal (VRE) Infections |
M. BASSETTI, D.A.CALLAN, L.M. DEMBRY, P.A. FARREL, J.E.TOPAL;
Yale Univ. School of Med. and Yale New Haven Hosp., New Haven, CT. |
|
|
Montag 17.12.01,
3:00 - 4:30 Uhr |
119. Antibiotic Resistance in Healthcare Settings |
1186. Risk Factors for Piperacillin-Tazobactam-Resistant Pseudomonas aeruginosa among Hospitalized Patients |
ANTHONY D. HARRIS1, E. P. PERENCEVICH1, M. C. ROGHMANN1, J. G. MORRIS1, K. S. KAYE2, J. A. JOHNSON1;
1Univ. of Maryland, Baltimore, MD, 2Duke Univ., Durham, NC. |
P.1
P.2
P.3
|
|
Montag 17.12.01,
15:00 Uhr |
100. Ketolide Susceptibility Studies |
Mikrobiologie von ABT-773. Siehe auch Beitrag 1001. |
Interview mit PD Dr. von Eiff, Münster |
|
|
Montag 17.12.01,
14:30 Uhr |
|
Clinical Pharmacy in the US
Research Studies presented at ICAAC 2001 |
Interview mit Dr. D. Nicolau, Hartford, CT, USA |
|
|
Montag 17.12.01,
14:00 Uhr |
|
"The higher the better" - PK/PD Views of an expert. |
Interview mit Prof. Dr. C. Nightingale, Hartford, CT, USA |
|
|
Montag 17.12.01,
13:30 Uhr |
|
Pneumokokken-Impfstoffe in der Pädiatrie |
Interview mit Prof. Dr. Dr. Dr. h.c. mult. Dieter Adam, München |
|
|
Montag 17.12.01,
13:00 Uhr |
185. Pediatric Infectious Diseases |
Pharyngitis-Studie; Diskussion der Ergebnisse. Siehe auch Beitrag 1826. |
Interview mit Prof. Dr. Dr. Dr. h.c. mult. Dieter Adam, München |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
103. Urinary Tract Infections |
1053. A Large Multicenter, Double-Blind Study of Ertapenem (ETP) vs. Ceftriaxone (CTX) in Complicated Urinary Tract Infections (CUTI) |
K. TOMERA1, E. BURDMANN2, O. PAMO3, R. GESSER4, Q. JIANG4, W. WIMMER4, THE PROTOCOL 014 STUDY GROUP;
1Alaska Clin. Res. Center, Anchorage, AK, 2Sao Jose do Rio Preto Med. School, Sao Paulo, Brazil, 3Peruvian Univ. Cayetano Heredia of Lima, Lima, Peru, 4Merck Res. Labs., West Point, PA. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
102. Novel Oxazolidinones II |
1048. Synthesis and Antibacterial Activity of Pyrrolopyridine-Substituted Oxazolidinones |
J. HILLIARD, R. GOLDSCHMIDT, J. FERNANDEZ, J. MELTON, S. PAGET, M. WEIDNER-WELLS, M. MACIELAG, K. BUSH;
The R.W. Johnson Pharmaceutical Res. Inst., Raritan, NJ. |
P.1
P.2
P.3
P.4
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
101. Novel Oxazolidinones I: AZD-2563 |
1026. In Vitro Activity of a Novel Oxazolidinone, AZD2563, against Gram-Positive Cocci, Including Diverse Multi-Resistant Isolates |
A. P. JOHNSON, M. WARNER, T. PARSONS, D. M. LIVERMORE;
Central Publ. Health Lab., Colindale, London, United Kingdom. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
101. Novel Oxazolidinones I: AZD-2563 |
1025. The New Oxazolidinone, AZD2563: the Effect of pH, Inoculum, Serum and Media Type on Antibacterial Activity |
P. J. TURNER, A. WOOKEY, J. M. GREENHALGH, M. EASTWOOD, J. CLARKE, J. CLARKE;
AstraZeneca, Macclesfield, Cheshire, United Kingdom. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
101. Novel Oxazolidinones I: AZD-2563 |
1024. Investigations into the Antibacterial Spectrum of the New Oxazolidinone, AZD2563, against Recent Clinical Isolates from North America and Europe |
P. J. TURNER, A. WOOKEY, J. M. GREENHALGH, M. EASTWOOD, J. CLARKE;
AstraZeneca, Macclesfield, Cheshire, United Kingdom. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
101. Novel Oxazolidinones I: AZD-2563 |
1023. In Vivo Studies of Novel Oxazolidinones with O- and N-linked C-5 Heterocyclic Side-Chains, Including AZD2563 |
M. B. GRAVESTOCK, M. J. BETTS, E. CHAWNER, L. DAWSON, A. MCGREGOR, S. D. MILLS, R. G. WILSON, L. WOODS, A. WOOKEY;
AstraZeneca, Macclesfield, Cheshire, United Kingdom. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1018. In Vitro Activity of Telithromycin against Clinical Isolates of Streptococcus pneumoniae Collected from 214 Medical Centers across the United States during the Winter of 2000/2001 |
C. W. STRATTON1, A. BARRY2, Y. C. YEE3;
1Vanderbilt Univ., Nashville, TN, 2CMI, Wilsonville, OR, 3Aventis Pharma, Bridgewater, NJ. |
P.1
P.2
P.3
P.4
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1008. In Vitro Activity of ABT-773 vs. Macrolide-Susceptible and -Resistant S. pneumoniae, H. influenzae and M. catarrhalis: Results of a 2 Year (1999/2000 and 2000/2001) Canadian Respiratory Organism Surveillance Study (CROSS) |
G. G. ZHANEL1, A. WIERZBOWSKI1, A. NOREDDIN1, K. NICHOL2, D. J. HOBAN2;
1University of Manitoba, Winnipeg, MB, Canada, 2Health Sciences Centre, Winnipeg, MB, Canada. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1007. In Vitro Activity of ABT-773 and Six Other Antibacterial Agents against Recent Community-Acquired Respiratory Tract Isolates: a German Multicenter Study |
S. BAGEL, J. BRAUERS, M. KRESKEN;
Antiinfectives Intelligence, Bonn, Germany. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1006. Susceptibility of Respiratory Pathogens in Great Britain to ABT-773, a New Ketolide Antibiotic |
THOMAS B. LYTLE, NICHOLAS G. WARWICK, STEVE J. COLES;
Abbott Laboratories, Maidenhead, United Kingdom. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1005. A Multi-Center Study Comparing the Activity of a Novel Ketolide ABT-773 with Beta-Lactams, Macrolides and Fluoroquinolones against Respiratory Tract Pathogens isolated in 2000-2001 in the the Province of Quebec, Canada |
K. WEISS1, C. RESTIERI1, H. GUAY1, P. DOLCE2, L. A. GALARNEAU3, P. HARVEY3, JF PARADIS2, H. SENAY2, AND THE GRAM NETWORK2, D. E. LOW4, C. LAFERRIERE2, I. LECORRE2;
1Hopital Maisonneuve-Rosemont, Montreal, Canada, 2GRAM, Montreal, Canada, 3The Gram Network, Montreal, PQ, Canada, 4Mount Sinai Hospital, Toronto, Canada. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1004. In Vitro Activity of ABT-773, a Novel Ketolide, against Clinical Isolates of Gram-Positive and Gram-Negative Cocci |
M. INOUE, Y. SATO, R. OYAUCHI, R. OKAMOTO;
Kitasato Univ., Kanagawa, Japan. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1003. Mutation Prevention Concentration (MPC) of ABT-773 (ABT) versus Four Other Agents against Streptococcus pneumoniae (SP) and Haemophilus influenzae (HF) |
M. M. NEUHAUSER1, J. L. PRAUSE2, S. L. PENDLAND2;
1University of Houston, Houston, TX, 2University of Illinois at Chicago, Chicago, IL. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1002. Activity of a New Ketolide ABT-773 In Vitro against S. pneumoniae Non-Susceptible to Penicillin or Macrolides |
EDWARD O. MASON1, L. B. LAMBERTH2, S. L. KAPLAN1, U.S. MULTICENTER PNEUMOCOCCAL SURVEILLANCE GROUP;
1Baylor College of Medicine, Houston, TX, 2Texas Children's Hospital, Houston, TX. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
100. Ketolide Susceptibility Studies |
1001. Comparative In Vitro Activity of ABT-773 and Two Macrolides against Staphylococci |
C. VON EIFF, G. PETERS;
Inst. of Med. Microbiol., Univ. of Münster, Hosp. and Clin., Münster, Germany. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
995. Efficacy of Linezolid in MRSA and Vancomycin-Insensitive Staphylococcus aureus (VISA) Hematogenous Pulmonary Infection Model |
K. YANAGIHARA, Y. KANEKO, M. KUROKI, Y. MIYAZAKI, Y. HIRAKATA, K. TOMONO, T. TASHIRO, S. KOHNO;
Nagasaki University, Nagasaki, Japan. |
P.1
P.2
P.3
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
994. Gatifloxacin: Efficacy in the Chinchilla Model of Streptococcus pneumoniae Acute Otitis Media |
JD SWARTS1,2, J. BATTI1,2, J. BANKS1, J. SEROKY1;
1Children's Hospital of Pittsburgh, Pittsburgh, PA, 2Univ. Pittsburgh Sch. Med., Pittsburgh, PA. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
993. The In Vivo Activities of ABT-773 in Mouse Models of Respiratory Tract Infection Due to Streptococcus pneumoniae and Haemophilus influenzae |
T. FUJIKAWA, S. MIYAZAKI, Y. ISHII, N. FURUYA, A. OHNO, T. MATSUMOTO, K. TATEDA, K. YAMAGUCHI;
Toho University School of Medicine, Tokyo, Japan. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
992. ABT-773 Demonstrates Bactericidal Effects against Susceptible and Resistant Streptococcus pneumoniae and Haemophilus influenzae in Rat Pulmonary Infection |
M. MITTEN, J. MEULBROEK, A. TOVCIMAK, G. WILKERSON, J. STAVROPOULOS, N. RAMER, A. NILIUS, Z. MA AND R. FLAMM;
Abbott Laboratories, Abbott Park, IL. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
990. Effect of Serum Protein Binding on the Outcome of Therapy with Gemifloxacin |
V. BERRY, R. STRAUB, G. WOODNUTT;
GlaxoSmithKline, Collegeville, PA. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
988. Efficacy of a Pharmacokinetically Enhanced Formulation of Amoxicillin/Clavulanate against Experimental Respiratory Tract Infection (RTI) in Rats Caused by Streptococcus pneumoniae (Sp) |
V. BERRY, C. SINGLEY, J. SATTERFIELD, G. WOODNUTT;
GlaxoSmithKline, Collegeville, PA. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
099. Respiratory Infections |
986. Effectiveness of ABT-773 in an Experimental Model of Multidrug-Resistant (MDR) Streptococcus pneumoniae (Sp) Bacteremic |
I. C. MICHELOW, R. D. HARDY, K. OLSEN, J. IGLEHART, B. B. ROGERS, H. JAFRI, G. H. MCCRACKEN, O. RAMILO;
Univ. of TX Southwestern Med. Ctr., Dallas, TX. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
097. Human Pharmacokinetics of Antimicrobials |
952. Clinical Safety of Pharmacokinetically Enhanced Amoxicillin/Clavulanate Compared with Currently Approved Formulations of Amoxicillin/Clavulanate |
M-P RICHARD1, B. WYNNE2;
1GlaxoSmithKline, Harlow, United Kingdom, 2GlaxoSmithKline, Collegeville, PA. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
097. Human Pharmacokinetics of Antimicrobials |
946. Tissue Penetration of Cefditoren (CEE) into Bronchial Mucosa (BM) and Epithelial Lining Fluid (ELF) in Patients Undergoing Fiberoptic Bronchoscopy |
M. KINZIG-SCHIPPERS1, M. HINDER2, K. GÖHLER2, U. LOOS3, F. VOGEL4, F. SORGEL1;
1IBMP, Nürnberg, Germany, 2Grünenthal GmbH, Aachen, Germany, 3Knappschaft Hosp., Recklinghausen, Germany, 4Hosp. Internal Medicine, Hofheim a. T., Germany. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
097. Human Pharmacokinetics of Antimicrobials |
942. Human Disposition and Metabolism of Orally Administered [14C]ABT773 |
Z. GUAN, S. FUKUMOTO, L. FAN, J. UCHIC, S. RAJA, K. MARSH, S. ROBERTS, M. EMERY;
Abbott Laboratories, Abbott Park, IL. |
|
|
Montag 17.12.01, 13:30 - 15.00 Uhr |
097. Human Pharmacokinetics of Antimicrobials |
941. ABT-773 Has No Clinically-Important Effect on the Pharmacokinetics and Safety of Theophylline |
LINDA E. GUSTAVSON, X. YE, J. BEASON, T. CHIRA, M. EWEN, M. PARIS, L. WILLIAMS;
Abbott Labs, Abbott Park, IL. |
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
087. Sexually Transmitted Diseases |
888. Results of a Phase III Randomized, Double-Blind Study of Ertapenem (ETP) vs Piperacillin/Tazobactam (P/T) for Acute Pelvic Infection (Inf) in Women |
S. ROY1, I. HIGAREDA2, E. ANGEL-MULLER3, M. ISMAIL4, B. DEYI5, C. HAGUE5, H. TEPPLER5, PROTOCOL 023 STUDY GROUP;
1Keck Sch. of Med.@USC, Los Angeles, CA, 2Nuevo Hos. Civil, Guadalajara, Mexico, 3Univ. Nacional de Col., Bogota, Colombia, 4Univ. of Chicago, Chicago, IL, 5Merck Res. Labs., West Point, PA. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
085. Community-Acquired Pneumonia |
870. Full Course Oral Levofloxacin vs. Intravenous (Ceftriaxone±Clarithromycin)-to-Oral Sequential Antibiotic Therapy for Patients Hospitalized with Community-Acquired Pneumonia (CAP) |
V. A. ERARD, P.-Y. BOCHUD, A. COMETTA, J. BILLE, O. LAMY AND T.CALANDRA;
CHUV, Lausanne, Switzerland. |
P.1
P.2
P.3
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
085. Community-Acquired Pneumonia |
855. A Double-Blind, Multicenter, Randomized, Phase III Study of Ertapenem (ETP) vs. Ceftriaxone (CTX) for Treatment of Serious Community-Acquired Pneumonia (CAP) |
N. VETTER1, E. CAMBRONERO-HERNANDEZ2, J. ROHLF3, S. SIMON4, A. SINGER5, R. ISAACS5, T. OLIVERIA5, THE PROTOCOL 020 STUDY GROUP;
1Pulmonary Ctr. of the City of Vienna, Vienna, Austria, 2Hosp. Cristiano Jerusalem, San Jose, Costa Rica, 3St. Francis Med. Ctr., Trenton, NJ, 4Southeast Res. Associates, Austell, GA, 5Merck Res. Labs., West Point, PA. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
082. Azole Antifungals In Vitro |
816. Novel Effect of Voriconazole on Conidiation and Pigmentation of Aspergillus Species |
N. L. VARANASI, I. BASKARAN, G. J. ALANGADEN, P. H. CHANDRASEKAR, E. K. MANAVATHU;
Wayne State University, Detroit, MI. |
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
807. In Vitro Activities of MK-0826 and Parenteral ß-Lactam Antimicrobials against Clinical Isolates of ESBL-Producing Klebsiella pneumoniae and in an Isogenic Host |
K. M. OLSEN, J.C. MCNABB, P.D. FEY, M.E. RUPP;
University of Nebraska Medical Center, Omaha, NE. |
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
806. Ertapenem (ETP), a New Antimicrobial: Comparative In Vitro Activity against Clinically Significant Anaerobes |
K. E. ALDRIDGE, D. ASHCRAFT;
Louisiana State University Health Sciences Center, New Orleans, LA. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
805. Pseudomonas aeruginosa Resistance to Imipenem (IMI), Ertapenem (ETP) and Other Antibiotics: Results of a Multicenter ICU Study |
I. R. FRIEDLAND, S. HARM, L. STINSON, D. GALLAGHER;
Merck & Co, West Point, PA. |
P.1
P.2
P.3
P.4
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
804. Comparative Activity of MK-0826 (Ertapenem) against Canadian Respiratory Isolates of Streptococcus pneumoniae (SPN) and Haemophilus influenzae (HI) |
D. J. HOBAN1, L. PALATNICK1, B. WESHNOWESKI1, K. NICHOL1, G. G. ZHANEL2;
1Health Sciences Centre, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, MB, Canada. |
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
803. Comparative In Vitro Activity of Ertapenem against Respiratory Tract Bacterial Pathogens |
PATRICIA SCOTT HICKS, L. CHERRY, K. DORSO, L. GERCKENS, L. LYNCH, M. ROSENBACH, P. SINCLAIR, D. SUBER, B. A. PELAK, M. R. MOTYL;
Merck and Co., Inc, Rahway, NJ. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
796. Susceptibility to Faropenem among Recent U.S. Isolates of S. pneumoniae, H. influenzae, and M. catarrhalis |
D. F. SAHM1, D. C. DRAGHI1, I. A. CRITCHLEY1, K. MURFITT1, M. E. JONES2, C. THORNSBERRY1, J. A. KARLOWSKY1;
1Focus Technologies/MRL, Herndon, VA, 2Focus Technologies/MRL, Hilversum, Netherlands. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
795. In Vitro Activity of Faropenem (FAR) against Genetically Characterized Isolates of Moraxella catarrhalis and Streptococcus pneumoniae |
F. J. SCHMITZ1, M. BOOS1, S. MAYER1, J. VERHOEF2, D. MILATOVIC2, A. C. FLUIT2;
1Univ. Hosp. Dusseldorf, Dusseldorf, Germany, 2Univ. Hosp Utrecht, Utrecht, Netherlands Antilles. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
794. Bactericidal Activity of Faropenem (FAR) vs. Other Oral Antibiotics against Recent Respiratory Tract Isolates |
I. MORRISSEY, D. BESTE, M. ROBBINS;
GR Micro Ltd, London, United Kingdom. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
793. In Vitro Activity of Faropenem against Pediatric Isolates |
D. ADAM;
Klinikum Innenstadt der LMU, Munich, Germany. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
792. In Vitro Activity of Faropenem (FAR) against Gram-Positive and Gram-Negative Bacteria |
D. MILATOVIC, A. C. FLUIT, J. VERHOEF;
Eijkman-Winkler Institute, University Utrecht, Utrecht, Netherlands Antilles. |
P.1
P.2
|
|
Montag 17.12.01, 11:00 - 12:30 Uhr |
081. Carbapenems In Vitro |
791. Faropenem: Activity against ESBL, AmpC, and Other ß-Lactamase-Producing Enterobacteriaceae |
J. A. BLACK1, E. SMITH MOLAND1, T. J. LOCKHART2, P. D. LISTER2, K. S. THOMSON1;
1Dept. Med. Microbiol. & Immunol., Creighton Univ. Sch. of Med., Omaha, NE, 2Dept. Med. Microbiol. & Immunol., Creighton Univ. Sch. of Med., omaha, NE. |
P.1
P.2
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
079. Infections in Neutropenic Patients |
776. Piperacillin/Tazobactam (PTZ) Use in Febrile Neutropenic Patients (FNP): a Meta-Analysis |
V. ZAROTSKY, G. S. JARESKO, P. D. HOLTOM;
University of Southern California Schools of Pharmacy and Medicine, Los Angeles, CA. |
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
079. Infections in Neutropenic Patients |
774. An EORTC-IATG Double-Blind Trial of Vancomycin (Van) versus Placebo (Pla) for Persistent Fever in Neutropenic Cancer Patients (NCP) given Piperacillin/tazobactam (PT) Monotherapy |
A. COMETTA, W. V. KERN, R. DEBOCK, M. PAESMANS, M. VANDENBERGH, F. CROKAERT, D. ENGELHARD, O. MARCHETTI, H. AKAN, H. BASSARIS, V. KORTEN, C. VISCOLI, M. P. GLAUSER, FOR THE INTERNATIONAL ANTIMICROBIAL THERAPY GROUPOF THE EORTC;
CHUV, Lausanne, Switzerland. |
P.1
P.2
P.3
P.4
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
079. Infections in Neutropenic Patients |
771. Cefepime Plus Amikacin versus Piperacillin-Tazobactam Plus Amikacin in the Treatment of Patients with Fever and Granulocytopenia |
L. GOMEZ, C. ESTRADA, I. GOMEZ, M. MARQUEZ, D. DALMAU, C. ESTANY, J. M. MARTI, J. GARAU;
Hospital Mutua Terrassa, Barcelona, Spain. |
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
078. Gastrointestinal Infections |
763. Piperacillin/Tazobactam (PTZ) Use in the Treatment of Intra-Abdominal Infections (IAI): a Meta-Analysis |
V. ZAROTSKY, G. S. JARESKO, P. D. HOLTOM;
University of Southern California Schools of Pharmacy and Medicine, Los Angeles, CA. |
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
076. BMS-284756 and Other Fluoroquinolones In Vitro |
735. Activity of Gemifloxacin, Ciprofloxacin and Levofloxacin against 8579 Respiratory Isolates Collected Worldwide in 2000 |
L. M. KOETH1, M. R. JACOBS2, D. FELMINGHAM3, J. A. POUPARD4, L. A. MILLER4, K. SAUNDERS4;
1Laboratory Specialists Inc, Westlake, OH, 2CWRU, Cleveland, OH, 3GR Micro Ltd, London, United Kingdom, 4GlaxoSmithKline, Collegeville, PA. |
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
076. BMS-284756 and Other Fluoroquinolones In Vitro |
726. Effect of Gemifloxacin on Viability of Chlamydia pneumoniae (Cpn) in a Continuous Infection Model In Vitro |
A. KUTLIN, P. M. ROBLIN, M. R. HAMMERSCHLAG;
SUNY Downstate Medical Center, Brooklyn, NY. |
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
075. Pneumococci, Fluoroquinolones and Resistance |
708. Quinolone-Resistant Pneumococci from Croatia |
GLENN A. PANKUCH1, K. NAGAI1, B. BOZDOGAN1, A. TAMBIC2, S. SCHOENWALD2, T. TAMBIC3, S. KALENIC4, S. PLESKO5, N. KUCISEC6, Z. KOTARSKI7, M. PAL8, P. APPELBAUM1;
1Hershey Medical Center, Hershey, PA, 2Univ Hospital of Infectious Diseases, Zagreb, Croatia, 3Croatian Acad Med Sci and Clin Hospital, Zagreb, Croatia, 4Rebro, Zagreb, Croatia, 5Univ Hospital of infectious Diseases, Zagreb, Croatia, 6Sveti Duh Hospital, Zagreb, Croatia, 7Univ Hospital Lung Diseases, Zagreb, Croatia, 8Public Health Lab, Cakovec, Croatia. |
P.1
P.2
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
075. Pneumococci, Fluoroquinolones and Resistance |
705. Activities of Respiratory Fluoroquinolones against Penicillin-Resistant S. pneumoniae Isolated in Six European Countries in 2000-01 |
M. E. JONES1, J. A. KARLOWSKY2, I. A. CRITCHLEY2, K. MURFITT2, R. S. BLOSSER2, C. THORNSBERRY2, D. F. SAHM2;
1Focus Technologies/MRL, Hilversum, Netherlands, 2Focus Technologies/MRL, Herndon, VA |
P.1
P.2
|
|
Montag 17.12.01, 09:30 - 11:00 Uhr |
075. Pneumococci, Fluoroquinolones and Resistance |
702. Prevalence of Single Mutations in Topoisomerase IV and DNA Gyrase among US Levofloxacin Susceptible Clinical Isolates of Streptococcus pneumoniae |
T. DAVIES1, S. PFLEGER1, A. EVANGELISTA1, K. BUSH2, D. SAHM3, R. GOLDSCHMIDT2;
1Ortho-McNeil Pharmaceutical, Raritan, NJ, 2The R. W. Johnson Pharmaceutical Res. Inst., Raritan, NJ, 3Focus Technologies, Herndon, VA. |
P.1
P.2
|
|
Sonntag 16.12.01, 15:00 - 16:30 Uhr |
049. GAR-936 Susceptibility Studies |
525. Comparison of the In Vitro Activity of GAR-936 with Tetracycline, Minocycline, and Doxycycline in Isolates of Nontuberculous Mycobacteria |
R. J. WALLACE JR, B. A. BROWN-ELLIOTT, C. J. CRIST, R. J. WALLACE;
The University of Texas Health Center, Tyler, TX. |
P.1
P.2
|
|
Sonntag 16.12.01, 15:00 - 16:30 Uhr |
049. GAR-936 Susceptibility Studies |
521. In Vitro Activity of GAR-936 against Gram-Positive and Gram-Negative Bacteria |
DANA MILATOVIC, A. C. FLUIT, J. VERHOEF;
Eijkman Winkler Institute, Utrecht, Netherlands. |
P.1
P.2
|
|
Sonntag 16.12.01, 14:00 - 16:30 Uhr |
042. Emergence and Prevention of Quinolone Resistance |
441. The Magnitude of the Pharmacodynamic Parameters which Predict Fluoroquinolone Antibacterial Effect (ABE) and Emergence of Resistance (EoR) Are Not Uniform for All Species |
A. P. MACGOWAN, K. E. BOWKER;
BCARE, Bristol, United Kingdom. |
|
|
Sonntag 16.12.01, 14:00 - 16:30 Uhr |
042. Emergence and Prevention of Quinolone Resistance |
440. The Pharmacodynamics of Emergence of Resistance (EoR) to Moxifloxacin in S. pneumoniae (Sp) and P. aeruginosa (Pa) Explored in an In Vitro Model of Infection |
A. P. MACGOWAN, K. E. BOWKER;
BCARE, Bristol, United Kingdom. |
P.1
P.2
|
|
Sonntag 16.12.01, 14:00 - 16:30 Uhr |
042. Emergence and Prevention of Quinolone Resistance |
438. Comparative Activity of Mutant Prevention Concentration (MPC)-Derived Dosages of Moxifloxacin (MXF) and Levofloxacin (LEV) against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model (IVPM) |
G. P. ALLEN1, M. J. RYBAK1,2; |
P.1
P. 2
|
|
Sonntag 16.12.01, 11:00 - 12:30 Uhr |
013. Quinolone Resistance |
148. Mutation Rates of Acinetobacter baumannii against Gemifloxacin, Moxifloxacin and Ciprofloxacin |
P. G. HIGGINS1, K. COLEMAN2, S. G. B. AMYES1;
1University of Edinburgh, Edinburgh, United Kingdom, 2GlaxoSmithKline, Collegeville, PA. |
P.1
P.2
|
|
Sonntag 16.12.01, 11:00 - 12:30 Uhr |
013. Quinolone Resistance |
142. Mechanisms of Resistance to Gemifloxacin in Comparison to Ciprofloxacin in Staphylococcus aureus |
D. INCE, L. C. SILVER, D. C. HOOPER;
Massachusetts General Hospital, Boston, MA. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
007. Surveillance of Antimicrobial Resistance |
79. Nationwide Survey of Pathogen Frequency and Antimicrobial Susceptibility Patterns from Community Hospitals throughout the United States |
K. W. GAREY1, M. MANDURU2, V. GUPTA2, L. H. DANZIGER1;
1University of Illinois at Chicago, Chicago, IL, 2Owen Healthcare, Inc, Chicago, IL. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
007. Surveillance of Antimicrobial Resistance |
65. Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program, USA: Trends in Resistance (R), Molecular Epidemiology and Antimicrobial Usage |
MICHAEL A. PFALLER1, R. N. JONES2, MYSTIC PARTICIPANTS GROUP2;
1University of Iowa College of Medicine, Iowa City, IA, 2The JONES Group/JMI Laboratories, North Liberty, IA. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
006. Resistance in Bacteria of Gastrointestinal Origin |
64. Trends in Antimicrobial Resistance of the Bacteroides fragilis Group over an 11-Year Period (1989-2000) |
C. BETRIU1, M. GOMEZ2, I. RODRIGUEZ-AVIAL2, B. A. SANCHEZ2, J. J. PICAZO2;
1Hospital Clinico San Carlos, Madrid, Spain, 2HOSPITAL CLINICO SAN CARLOS, MADRID, Spain. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
006. Resistance in Bacteria of Gastrointestinal Origin |
62. Antibiotic Resistance among 547 Anaerobes from Chicago Area Medical Centers |
DAVID W. HECHT, J. R. OSMOLSKI;
Loyola University Medical Center, Maywood, IL. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
005. Pharmacokinetics of Quinolones in Children and Adults |
49. Pharmacodynamic Activity of Gatifloxacin on Streptococcus pneumoniae and Staphylococcus aureus in Skin Blister Fluid |
A. TRAMPUZ, U. FLUCKIGER, G. LAIFER, W. ZIMMERLI;
University Hospitals, Basel, Switzerland. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
005. Pharmacokinetics of Quinolones in Children and Adults |
48. Possible Role of Drug Photodegradation in Fluoroquinolone (FQ)-Induced Phototoxicity in Mice |
E. WAKABAYASHI, Y. KITAMURA, Y. KUNINISHI, C. KOBAYASHI, N. ISHIKAWA, Y. MASUMOTO, H. KUSAJIMA;
Res. Ctr., Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
005. Pharmacokinetics of Quinolones in Children and Adults |
42. Single-Dose Pharmacokinetics and Tolerability of Intravenous Levofloxacin in Pediatric Patients |
S. CHIEN1, R. ABELS1, J. BLUMER2, A. CHOW1, H. GOLDSTEIN1, G. KEARNS3, S. MALDONADO4, G. NOEL1, T. WELLS5, S. SPIELBERG4;
1The R.W.Johnson Pharmaceutical Research Institute, Raritan, NJ, 2Rainbow Babies and Children's Hospital PPRU, Cleveland, OH, 3Children’s Mercy Hospital PPRU, Kansas City, MO, 4Janssen Research Foundation, Titusville, NJ, 5Arkansas Children's Hospital PPRU, Little Rock, AR. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
005. Pharmacokinetics of Quinolones in Children and Adults |
39. Single Dose Safety and Pharmacokinetics (PK) of Intravenous (IV) Gatifloxacin in Pediatric Patients |
M. AVILA-AGUERO1, J. BLUMER2, J. BRADLEY3, X. SAEX-LLORENS4, M. O'RYAN5, D. GRASELA6, F. LACRETA6, M. SWINGLE6, G. MCCRACKEN7, H. JAFRI7;
1Hosp. Nacional de Ninos, San Jose, Costa Rica, 2Case Western Reserve PPRU, Cleveland, OH, 3UC San Diego Children's Hosp. PPRU, San Diego, CA, 4Hosp. del Nino, Ciudad de Panama, Panama, 5Univ. de Chile, Santiago, Chile, 6Bristol-Myers Squibb, Princeton, NJ, 7UT Southwestern Med. Ctr., Dallas, TX. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
005. Pharmacokinetics of Quinolones in Children and Adults |
38. Population Pharmacokinetic Analysis of Gatifloxacin in Pediatric Patients |
C. RUBINO1, B. CIRINCIONE1, R. PENDLETON1, D. GRASELA2;
1Cognigen Corp., Buffalo, NY, 2Bristol-Myers Squibb, Princeton, NJ. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
005. Pharmacokinetics of Quinolones in Children and Adults |
37. Gatifloxacin in Children with Recurrent Otitis Media (ROM): Application of Real-Time Data Assembly (RTDA) and Sparse PK Sampling in Clinical Development |
D. GRASELA1, C. RUBINO2, F. LACRETA1, A. ARGUEDAS3, L. SHER4, E. LOPEZ5, X. SAEZ-LORENZ6, M. SWINGLE1, B. CIRINCIONE2, M. SOKOLOWSKI2, P. PIERCE1;
1Bristol-Myers Squibb, Princeton, NJ, 2Cognigen Corp., Buffalo, NY, 3Inst. Costarricense de Investigaciones Clin., San Jose, Costa Rica, 4Peninsula Res. Inst., Rolling Hills Est., CA, 5Hosp. de Ninos "Ricardo Gutierrez", Buenos Aires, Argentina, 6Hosp. del Nino, Ciudad de Panama, Panama. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals |
31. Fluconazole in Anuric Patients Undergoing Continuous-Veno-Venous-Hemodialysis (CVVHD): Pharmacokinetics and Dosage Simulation |
S. C. MUELLER1, J. MAJCHER-PESZYNSKA1, R. G. MUNDKOWSKI1, H. HICKSTEIN2, B. DREWELOW1;
1Clinical Pharmacology, University of Rostock, Rostock, Germany, 2Nephrology, University of Rostock, Rostock, Germany. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals |
22. Potentiation of Voriconazole (VCZ) Ocular Penetration by Topical Latanoprost (LT) Co-Administration |
W. E. SPONSEL1, V. BERNALL1, G. PARIS2, Y. TRIGO1, M. PENA1, R. GLICKMAN1, J. R. GRAYBILL1;
1The Univ. of TX Health Sci. Ctr. at San Antonio, San Antonio, TX, 2The Univ. of Tx Health Sci. Ctr. at San Antonio, San Antonio, TX. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals |
21. Voriconazole Inhibition of Tacrolimus Metabolism after Liver Transplantation and in Human Liver Microsomes |
N. SINGH, S. ZHANG, T. GAYOWSKI, R. VENKATARAMANAN;
Univ. of Pitts., Pittsburgh, PA. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals |
17. Pharmacokinetics of Intravenous Voriconazole in Children after Single and Multiple Dose Administration |
T. J. WALSH1, A. ARGUEDAS2, T. DRISCOLL2, P. ADAMSON2, M. KARLSSON2, N. WOOD3, P. MILLIGAN4, I. LUTSAR4;
1Voriconazole Pediatric Study Group, Bethesda, MD, 2Voriconazole Pediatric Study Group, BETHESDA, MD, 3Pfizer Global Research and Development, Sandwich, Kent, United Kingdom, 4Pfizer Global Research and Development, SANDWICH, Kent, United Kingdom. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals |
16. Multiple-Dose Pharmacokinetics of Voriconazole in Chronic Hepatic Impairment |
K. K. C. TAN1, N. WOOD2, A. WEIL3;
1Pfizer Global Research and Development, Sandwich, Kent, United Kingdom, 2Pfizer Global Research and Development, SANDWICH, Kent, United Kingdom, 3APEX Research, Munich, Germany. |
|
|
Sonntag 16.12.01, 9:30 - 11:00 Uhr |
004. Human Pharmacokinetics and Drug-Drug Interactions of Antifungals |
14. Effect of Hepatic Insufficiency on the Pharmacokinetics of Caspofungin |
J. STONE1, S. HOLLAND1, S. LI1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, S. BI1, M. FRIEL1, G. MISTRY1, S. DILZER2, K. LASSETER2;
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL. |
|
|
Samstag 15.12.01, 17.15 Uhr |
Vorsymposium |
PROTEKT – Beschreibung eines neuen Surveillance Programmes. www.protekt.org.
Symposiumsunterlagen |
Interview von Dr. Harding, UK
mit Prof. Grünberg, UK |
|
|
Samstag, 15.12.01, 16.15 Uhr |
Vorsymposium |
Interview von Frau OÄ Dr. Grabein und Herrn OA Dr. Bodmann über die Behandlung der nosokomialen Pneumonie |
Interview von Dr. med. B. Grabein mit Dr. med. K.-F. Bodmann |
|
